You searched for Parkinson's - Page 2 of 20

News and Trends 12 May 2017

UPDATE: Italian Pharma receives €11M for Parkinson’s Drug Approval

…an Italian biotech focused on CNS diseases, is on a roll. The latest win? FDA approval of its Parkinson’s drug, Xadago. Just in time for World Parkinson’s Day on April…

May 12, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 16 Jan 2018

Two Proteins in the Brain Could Protect Against and Repair the Damage Caused by Parkinson’s

…neurons of patients with Parkinson’s disease. VEGF and GDNF significantly reduced the loss of dopaminergic neurons and stimulated the production of new nerve cells. Current Parkinson’s therapies improve symptoms but…

January 16, 2018 - 3 minutesmins - By Alex Dale

News and Trends 28 Nov 2017

New Gene Therapy for Parkinson’s will be Developed in the UK

…developed by Synpromics in the development of a gene therapy for young-onset Parkinson’s disease (YOPD) in patients that start showing Parkinson’s symptoms before 50. Gene therapy for Parkinson’s is not…

November 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Jul 2017

Roche and Ireland’s Biggest Biopharma Take Their Parkinson’s Antibody to Phase II

Prothena and Roche are advancing their Parkinson’s antibody to Phase II, triggering a new milestone payment from what is proving a lucrative deal for Prothena. Prothena, the largest biopharma in…

July 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 4 Jul 2024

Parkinson’s disease: biotech’s pursuit for more therapies

…were also able to distinguish between Parkinson’s disease and Parkinsonism – an umbrella term used for neurological disorders similar to Parkinson’s, often characterized by tremors, slow movement and stiffness. Soon…

July 4, 2024 - 10 minutesmins - By Roohi Mariam Peter

News and Trends 16 Nov 2015

Swissmedic Approves Zambon and Newron Therapy against Parkinson’s

Italian Pharma Newron and its partner Zambon (from Milan) have been granted a license by Swissmedic (the regulatory agency in Switzerland) for Xadago, a new combo ‘add-on’ therapy for Parkinson’s…

November 16, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 7 Feb 2017

Swiss Parkinson’s Biotech raises Massive €29M in Series B from Top European VCs

Top European VCs have invested €29M in Prexton Therapeutics to support two Phase II trials of its lead candidate foliglurax in Parkinson’s. An international team of top European biotech investors…

February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

lundbeck prexton therapeutics acquisition parkinsons

News and Trends 16 Mar 2018

Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech

Lundbeck is acquiring Prexton Therapeutics in a deal that could reach up to €905M if the Swiss company’s Parkinson’s treatment proves successful. Danish pharma Lundbeck has decided to boost its…

March 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Sep 2016

ITW: Prexton Therapeutics CEO explains Development of new Parkinson’s Drug

For our first interview at the SACHS Conference in Basel yesterday, I met with François Conquet, founder and CEO of Prexton Therapeutics. His company’s treatment for Parkinson’s Disease just passed…

September 28, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 10 Jul 2017

Swiss Biotech Starts Phase II Trial to Treat Motor Symptoms of Parkinson’s

…day when the medication wears off and symptoms get worse. Traditional approaches like the administration of levodopa target dopaminergic neurons, whose activity is affected by Parkinson’s. However, as the disease…

July 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Stefan Weber CEO Newron Pharmaceuticals Labiotech Meetup Munich

Interview 20 Apr 2017

Newron’s Journey to Launch the First Parkinson’s Drug in 11 Years

…than current medications to patients with Parkinson’s. Stefan discussed how failure can be an important part of success and what being European means in biotech. After struggling with the FDA…

April 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Jun 2016

Vienna-based Biotech raises €10M to fight Metabolic diseases and Parkinson’s

…are high cholesterol, diabetes, Alzheimer’s and Parkinson’s. Its vaccines are short synthetic peptides created with Affitome, AFFiRiS’ proprietary platform. These short peptides function as B-cell epitopes, mimicking the part of…

June 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Parkinson's

UPDATE: Italian Pharma receives €11M for Parkinson’s Drug Approval

Two Proteins in the Brain Could Protect Against and Repair the Damage Caused by Parkinson’s

New Gene Therapy for Parkinson’s will be Developed in the UK

Roche and Ireland’s Biggest Biopharma Take Their Parkinson’s Antibody to Phase II

Parkinson’s disease: biotech’s pursuit for more therapies

Swissmedic Approves Zambon and Newron Therapy against Parkinson’s

Swiss Parkinson’s Biotech raises Massive €29M in Series B from Top European VCs

Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech

ITW: Prexton Therapeutics CEO explains Development of new Parkinson’s Drug

Swiss Biotech Starts Phase II Trial to Treat Motor Symptoms of Parkinson’s

Newron’s Journey to Launch the First Parkinson’s Drug in 11 Years

Vienna-based Biotech raises €10M to fight Metabolic diseases and Parkinson’s

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!